Inspec

Inspec Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Inspec (6656.T) as of Nov 13, 2026 is -3.01. In the previous year, Net Debt to Free Cash Flow Ratio was 2.47 — a change of -222.10% (lower).

Net Debt/FCF

-3.01

YoY

-222.10%

Last updated:

Net Debt to Free Cash Flow Ratio of Inspec is 2026 -3.01 . Net Debt to Free Cash Flow Ratio of Inspec was 2025 2.47 . It decreases by -222.10% lower compared to the previous year.

The Inspec Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2019
-0.27 JPY
Jan 1, 2020
-0.70 JPY
Jan 1, 2021
-1.90 JPY
Jan 1, 2022
-2.25 JPY
Jan 1, 2023
-2.21 JPY
Jan 1, 2024
82.29 JPY
Jan 1, 2025
2.47 JPY
Jan 1, 2026
-3.01 JPY
The Inspec Net Debt/FCF history
YEARNet Debt/FCFYoY
-3.01-222.10%
2.47-97.00%
82.29-3,823.33%
-2.21-1.85%
-2.25+18.34%
-1.90+173.12%
-0.70+159.19%
-0.27-69.42%
-0.88-365.00%
0.33-94.78%
6.35-197.15%
-6.54+728.30%
-0.79—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inspec Stock analysis

What does Inspec do? inspec Inc. generates revenue through three primary segments. The Semiconductor Package Substrates and Precision Substrate Inspection Equipment segment sells appearance inspection equipment for semiconductor package substrates and precision printed circuit boards used in smartphones, tablets, PCs, and wearable terminals. The Precision Substrate Manufacturing Equipment segment provides photoplotters, inkjet printers, and direct imaging devices along with maintenance services for printed circuit boards. The Digital Pathology Related Equipment segment develops and sells medical image processing systems, specifically whole slide imaging (WSI) for digital pathology applications. Customers include manufacturers of advanced digital devices requiring semiconductor inspection, PCB producers needing photoplotters and imaging devices, and healthcare providers utilizing whole slide imaging systems for pathology diagnostics. The company's products target the semiconductor, electronics manufacturing, and medical imaging sectors with specific applications in device assembly, PCB production, and medical diagnostics. inspec Inc. focuses on equipment for semiconductor package substrates, precision substrates, and digital pathology, serving clients in the electronics and healthcare industries. The firm's inspection and imaging solutions are tailored to meet the quality control needs of high-tech manufacturing and medical diagnostics, with no mention of additional revenue streams beyond these three segments. Inspec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inspec stock

Net Debt to Free Cash Flow Ratio of Inspec is -3.01 in 2026.

Net Debt to Free Cash Flow Ratio of Inspec changed from 2.47 to -3.01, representing a -222.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Inspec since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Inspec with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Inspec

All Key Metrics — Inspec